NJ-OPEX/VANAS
30.11.2021 13:02:11 CET | Business Wire | Press release
OPEX® Corporation , a global provider of innovative warehouse, document and mail automation solutions, has entered into a new partnership with Vanas Engineering , a leading provider of intralogistics warehouse solutions and software that will help customers throughout Belgium, the Netherlands and Luxembourg (Benelux) identify and install the most efficient and productive warehouse management solutions for its businesses. The terms of the agreement are not public.
“OPEX was looking for a strong partner to expand our reach in Benelux, a target market for our products and services,” said Nicolas Dewit, Warehouse Automation Director of Business Development for OPEX Europe, Middle East and Africa (EMEA). “The people at Vanas are experts at intralogistics warehouse solutions and in helping their customers find innovative technology to propel their business forward. That customer-centric approach matches our own. Together, we are excited to provide a seamless solution for automation that maximizes warehouse space, and manages peaks and demands, without additional labor.”
OPEX offers dynamic eCommerce fulfillment solutions that utilize scalable warehouse robots to provide speed and accuracy, and streamline the supply chain from inventory storage and picking to sorting and shipping.
In addition, OPEX provides micro-fulfillment technology that optimizes space and helps execute flawless last-mile delivery, and offers reverse logistics solutions that improve returns, exchange operations and revenue with maximum speed and reduced labor.
“We are constantly looking for new technologies that can raise performances and bring added value to our customers,” said Andy Van Mieghem, Managing Director, Vanas Engineering. “OPEX delivers value, using unique innovative technology called iBOT® robotic vehicles, which we see benefitting our customers. The Perfect Pick® solution will bring a strong picking and retrieval system to the Benelux region that includes picking stations with speeds up to 500 order lines per pick station, while the Sure Sort® is a unique vertical sorting system which fits in a very small footprint.”
Mieghem adds, “I’m convinced that by offering OPEX solutions, this will encourage several of our customers in Benelux to automate. The fact that it’s a proven technology for years in the USA generates confidence for us as an integrator and for our end-customers.”
OPEX also offers document and mail automation solutions that offer seamless and secure mail sorting , document imaging and payment processing to improve business workflow and throughput, while reducing or eliminating intensive document preparation.
About
OPEX Corporation provides Next Generation Automation, including warehouse, document and mail automation solutions, to customers around the globe. With headquarters in Moorestown, NJ―and facilities in Pennsauken, NJ; Plano, TX (Dallas metro); France; Germany; Switzerland; and the United Kingdom―OPEX has more than 1,450 employees committed to reimagining and delivering innovative, scalable, unique technology solutions to solve the business challenges of today.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005406/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
